ScinoPharm Taiwan Continues Strategic Expansion in Formulation and CDMO Businesses

ScinoPharm Taiwan (Stock Code: 1789) held an online investor conference today to report its financial results for the first half of 2025. The company recorded consolidated revenue of US$45.2 million, equivalent to NT$1.434 billion, and a net profit after tax of NT$80 million. Despite revenue being affected by delayed orders from proprietary API customers and slower product sales from CDMO clients, ScinoPharm Taiwan maintained stable gross margins through proactive product portfolio optimization and cost control.

Operating in an environment of global political and economic uncertainty and significant exchange rate fluctuations—particularly the sharp appreciation of the New Taiwan Dollar against the U.S. Dollar—the company’s export-driven business experienced foreign exchange pressure impacting profitability.

Core Business Focus: Proprietary APIs, Formulations, and CDMO
ScinoPharm Taiwan continues to focus on its three core business pillars: proprietary APIs, proprietary formulations, and contract development and manufacturing (CDMO). In its proprietary API business, two additional oncology products completed Drug Master File (DMF) registration in the first half of 2025, bringing the company’s total to 79 registered products. The company continues to enhance its manufacturing flexibility and capacity to respond to price competition while consolidating its role in the global supply chain. ScinoPharm also continues to expand its customer base and market reach across China, Europe, and South America, maximizing product value through diversified market deployment.

For proprietary formulations, ScinoPharm focuses on developing high-value drug–device combination products targeting oncology, hematology, metabolic, and central nervous system (CNS) disorders. The company has initiated regulatory submissions and commercial strategies starting with the U.S. market, while extending to Europe, Asia, and South America. Currently, three products are under review by the U.S. FDA, and in Taiwan, the company has submitted registration applications for both oncology and diabetes drugs.

These Taiwan submissions not only advance domestic market entry but also lay a solid foundation for future global expansion. The company will further strengthen its strategic partnerships and accelerate the development of modified new drugs to enhance its competitive edge.

In its CDMO operations, ScinoPharm’s business teams continue to focus on specialized areas such as peptides, steroids, and cytotoxic compounds. The company actively showcases its technical strengths at international exhibitions to attract new partnerships with innovative drug developers. Leveraging its advanced production capacity and expertise, ScinoPharm continues to expand its portfolio of contract manufacturing projects and serve a broader range of global clients. Through its integrated API-to-drug product services, ScinoPharm strives to become a preferred global manufacturing partner for both APIs and formulations.

Advancing Oncology R&D and Supporting Taiwan’s Healthcare Resilience
As Taiwan’s National Health Insurance Administration (NHIA) promotes policies to strengthen local drug supply resilience—particularly through expanded incentive programs for domestically produced oncology generic drugs covering breast, colorectal, and lung cancers—ScinoPharm’s oncology expertise aligns closely with these national initiatives. In response, ScinoPharm Taiwan is leveraging its technical leadership in high-barrier oncology APIs and formulations to advance local manufacturing capabilities, secure policy advantages, and offer Taiwanese patients more diverse and high-quality treatment options.